Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Al-Kali, Aref [1 ]
Jones, Dan [1 ]
Cortes, Jorge [1 ]
Faderl, Stefan [1 ]
Ao, Xue [1 ]
Garcia-Manero, Guillermo [1 ]
Borthakur, Gautam [1 ]
Konopleva, Marina [1 ]
Brandt, Mark [1 ]
Andreeff, Michael [1 ]
Kantarjian, Hagop [1 ]
Ravandi, Farhad [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：820 / 821
页数：2
相关论文
共 50 条
  • [41] A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Bouligny, Ian M.
    Kantarjian, Hagop M.
    Yilmaz, Musa
    Daver, Naval
    Borthakur, Gautam
    Dinardo, Courtney D.
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Valero, Yesid Alvarado
    Jabbour, Elias
    Jain, Nitin
    Pemmaraju, Naveen
    Hammond, Danielle
    Chien, Kelly S.
    Takahashi, Koichi
    Issa, Ghayas C.
    Abbas, Hussein A.
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2024, 144 : 735 - 736
  • [42] Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry.
    Pollyea, Daniel Aaron
    George, Tracy
    Foucar, Kathryn M.
    Erba, Harry Paul
    Thompson, Michael A.
    Abedi, Mehrdad
    Roboz, Galli J.
    Landau, Danny
    Pagel, John M.
    Seiter, Karen
    Cogle, Christopher R.
    Nifenecker, Melissa
    Swern, Arlene S.
    Kiselev, Pavel
    Sugrue, Mary M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
    Hui Liu
    Rong Fu
    Lijuan Li
    Guojin Wang
    Jia Song
    Erbao Ruan
    Huaquan Wang
    Yuhong Wu
    Xiaoming Wang
    Kai Ding
    Zonghong Shao
    Clinical Drug Investigation, 2017, 37 : 167 - 174
  • [44] Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
    Liu, Hui
    Fu, Rong
    Li, Lijuan
    Wang, Guojin
    Song, Jia
    Ruan, Erbao
    Wang, Huaquan
    Wu, Yuhong
    Wang, Xiaoming
    Ding, Kai
    Shao, Zonghong
    CLINICAL DRUG INVESTIGATION, 2017, 37 (02) : 167 - 174
  • [45] Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, Nebiyou
    Yang, Rui
    Ravandi, Farhad
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Konopleva, Marina
    Faderl, Stefan
    Cortes, Jorge E.
    Brandt, Mark
    Hu, Yumin
    McCue, Deborah
    Newsome, Willie Mae
    Pierce, Sherry
    DeLima, Marcos
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 346 - 347
  • [46] Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study
    Abbenante, Mariachiara
    Papayannidis, Cristina
    Iacobucci, Ilaria
    Candoni, Anna
    Paolini, Stefania
    Malagola, Michele
    Emanuela, Ottaviani
    Lonetti, Annalisa
    Curti, Antonio
    Parisi, Sarah
    Testoni, Nicoletta
    Lama, Barbara
    Baccarani, Michele
    Martinelli, Giovanni
    CANCER RESEARCH, 2011, 71
  • [47] Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML)
    Mathisen, Michael S.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Pemmaraju, Naveen
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    O'Brien, Susan
    Quintas-Cardama, Alfonso
    Ghanem, Hady
    Daver, Naval G.
    Pierce, Sherry A.
    Lira, Cynthia
    Faderl, Stefan
    Jabbour, Elias
    BLOOD, 2012, 120 (21)
  • [48] Efficient Identification of Response to Cytarabine Idarubicin in Newly Diagnosed Acute Myeloid Leukemia by a New Individualized Medicine Test Based on ex vivo Pharmacology
    Montesinos, Pau
    Martinez, David
    Martinez-Lopez, Joaquin
    Sierra, Jorge
    Perez, Jaime
    Garcia, Raimundo
    Serrano, Josefina
    Fernandez, Pascual
    Herrera, Pilar
    Fernandez, Angeles
    Alonso, Arancha
    Bethancourt, Concepcion
    Gonzalez, Ataulfo
    Rodriguez-Macias, Gabriela
    Villoria, Jesus
    Troconiz, Inaki
    Bennett, Teresa
    Ballesteros, Joan
    Moscardo, Federico
    Angel Sanz, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 : S118 - S119
  • [49] Combination of Omacetaxine Mepesuccinate (homoharringtonine) and Sorafenib As an Effective Regimen for Acute Myeloid Leukemia (AML) Carrying FLT3-ITD
    Leung, Garret M. K.
    Zhang, Chunxiao
    To, Alan W. L.
    Lam, Stephen S. Y.
    Kwong, Yok Lam
    Leung, Anskar
    BLOOD, 2017, 130
  • [50] Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions
    Goldberg, Aaron D.
    Coombs, Catherine C.
    Wang, Eunice S.
    Walter, Roland B.
    Karanes, Chatchada
    Vigil, Carlos Enrique
    Messahel, Boo
    Stone, Richard M.
    Collins, Robert H.
    BLOOD, 2019, 134
12345